Amarin Corporation plc (NASDAQ:AMRN) today announced a series of
appointments and leadership changes to its Board of Directors,
including:
- Appointment of Erin Enright and Alfonso “Chito” Zulueta to the
Board, effective immediately. Ms. Enright and Mr. Zulueta will
stand for re-election to the Board at the Company’s 2022 Annual
Meeting in June.
- Per Wold-Olsen, a director since January 2022, has been named
Chairman of the Board, effective immediately. Mr. Wold-Olsen will
stand for re-election to the Board at the Company’s 2022 Annual
Meeting in June.
- As part of a planned retirement, David Stack, a director since
2012, and Joe Zakrzewski, a director since 2010, will retire from
the Board, effective at the close of the 2022 Annual Meeting.
- Mr. Wold-Olsen has been named Chair of the Remuneration
Committee; Ms. Enright has been named Chair of the Audit
Committee.
- Dr. Lars Ekman will remain a member of the Board.
“Today’s announcement advances the Company’s ongoing efforts
initiated in October 2021 to expand the expertise and diversity of
our Board and Company. These Board changes signal our commitment to
Amarin’s strategic plan to drive sustainable and profitable growth,
and ensure we have the additional skillsets and experience to
support Amarin’s current strategy, including significant experience
in finance, technology, portfolio diversification, operational
excellence and international commercial operations and strategy,”
said Mr. Wold-Olsen. “Both Erin and Alfonso are highly respected
leaders with proven track records in their respective fields and
bring strong and relevant expertise to contribute to the ongoing
execution of our three-pillar growth strategy. Erin’s deep
investment banking and capital markets experience, specifically
within the healthcare space, and Alfonso’s unique knowledge of
international markets and global marketing will enable them to
immediately add value to our Board.”
Mr. Wold-Olsen continued, “On behalf of the entire Board, I want
to thank Lars for his steadfast leadership as Chairman for the last
eight years, during which time Amarin delivered one of the most
important cardiovascular outcomes trials in recent times. I am
pleased that we will continue to benefit from his invaluable
insights as an ongoing member of our Board. We also extend our
deepest gratitude to David and Joe for their distinguished service
and innumerable contributions to Amarin over the years.”
Ms. Enright brings more than 30 years of experience as a
healthcare company executive and investor. She currently serves as
Managing Partner at Prettybrook Partners, overseeing approximately
20 active investments in a variety of healthcare companies. Prior
to her role at Prettybrook, Ms. Enright served as Chief Financial
Officer of InfuSystem and as President of Lee Medical.
Mr. Zulueta has more than three decades of experience in global
strategic and leadership roles within large pharma, specifically
with Eli Lilly and Company. At Eli Lilly, he held key senior
positions including Vice President of Global Marketing, head of the
Company’s Asia Region, and most recently as President of
International responsible for all geographies outside the United
States and Canada.
Following the 2022 Annual Meeting - with the addition of Ms.
Enright and Mr. Zulueta, and the planned retirements of Mr. Stack
and Mr. Zakrzewski - the Amarin Board will comprise eight
directors, seven of whom are independent.
About Erin Enright
Ms. Enright has served as a Managing Partner of Prettybrook
Partners since 2012. Prior to that, she served as Chief Financial
Officer of InfuSystem from 2005 to 2007, and as President of Lee
Medical, a medical device manufacturer, from 2004 to 2013. From
1993 to 2003, Ms. Enright was with Citigroup, where she was
Managing Director in its Equity Capital Markets group. While at
Citigroup, Ms. Enright was Chairperson of the firm’s Institutional
Investors Committee, responsible for screening and approving the
firm’s participation in equity underwritings and a member of the
Citigroup Global Equity Commitment Committee, responsible for
reviewing and approving the firm’s underwritings. She began her
career as an attorney with Wachtell, Lipton, Rosen & Katz.
Ms. Enright currently serves as Chairman of the Board of
Dynatronics Corporation, a director of the Medical Facilities
Corporation Board serving as Audit and Investment Committee Chair,
a member of the Board and Chair of the Audit Committee of Brooklyn
ImmunoTherapeutics (NASDAQ:BTX), and a director of Keystone Dental,
a privately held company where she serves as Audit Committee Chair.
She has previously served as a director at Biolase, Inc., Tigerlabs
and Ceelite Corporation.
Ms. Enright received her A.B. degree from the School of Public
and International Affairs at Princeton University and J.D. degree
from the University of Chicago Law School.
About Alfonso “Chito” Zulueta
Prior to Mr. Zulueta’s retirement in 2021, he spent over three
decades at Eli Lilly and Company in various roles of increasing
responsibility, including most recently as President, International
from 2017 until his retirement. He was a corporate officer and
member of Eli Lilly and Company’s executive committee.
Mr. Zulueta currently serves on the Board of CTS Corporation
where he serves on the audit and nominating and governance
committees and Syneos Health as well as Glooko and Calidi
Biotherapeutics, both privately held companies. He previously
served as a member of the board of the European Federation of
Pharmaceutical Industries and Associations (EFPIA), and US-Japan
Business Council.
He received his Bachelor of Arts from De La Salle University in
the Philippines, and his MBA from Colgate Darden Graduate School of
Business Administration at the University of Virginia.
About Amarin
Amarin is an innovative pharmaceutical company leading a new
paradigm in cardiovascular disease management. From our scientific
research foundation to our focus on clinical trials, and now our
global commercial expansion, we are evolving and growing rapidly.
Amarin has offices in Bridgewater, New Jersey in the United States,
Dublin, in Ireland, Zug in Switzerland, and other countries in
Europe as well as commercial partners and suppliers around the
world. We are committed to rethinking cardiovascular risk through
the advancement of scientific understanding of the impact on
society of significant residual risk that exists beyond traditional
therapies, such as statins for cholesterol management.
Availability of Other Information About
Amarin
Amarin communicates with its investors and the public using the
company website (www.amarincorp.com) and the investor relations
website (investor.amarincorp.com), including but not limited to
investor presentations and FAQs, Securities and Exchange Commission
(“SEC”) filings, press releases, public conference calls and
webcasts. The information that Amarin posts on these channels and
websites could be deemed to be material information. As a result,
Amarin encourages investors, the media and others interested in
Amarin to review the information that is posted on these channels,
including the investor relations website, on a regular basis. This
list of channels may be updated from time to time on Amarin’s
investor relations website and may include social media channels.
The contents of Amarin’s website or these channels, or any other
website that may be accessed from its website or these channels,
shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of U.S. securities laws. These forward-looking
statements are not promises or guarantees and involve substantial
risks and uncertainties. A list and description of these risks,
uncertainties and other risks associated with an investment in
Amarin can be found in Amarin's filings with the SEC, including
Amarin’s annual report on Form 10-K for the year ended
December 31, 2021, and quarterly report on Form 10-Q for the
quarter ended March 31, 2022. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date they are made. Amarin
undertakes no obligation to update or revise the information
contained in its forward-looking statements, whether as a result of
new information, future events or circumstances or otherwise.
Amarin’s forward-looking statements do not reflect the potential
impact of significant transactions the company may enter into, such
as mergers, acquisitions, dispositions, joint ventures or any
material agreements that Amarin may enter into, amend or
terminate.
Amarin Contact Information
Investor Inquiries:Lisa DeFrancescoInvestor Relations Amarin
Corporation plcinvestor.relations@amarincorp.com (investor
inquiries)
Media Inquiries:Mark MarmurCorporate Communications, Amarin
Corporation plcPR@amarincorp.com (media inquiries)
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2024 to May 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From May 2023 to May 2024